top of page

MSD announces positive results from elbasvir/grazoprevir HCV study

MSD has announced results from the Phase III C-EDGE: Head-to-head trial evaluating the efficacy and safety of the investigational once-daily, fixed-dose combination tablet elbasvir/grazoprevir versus a regimen of sofosbuvir plus peginterferon and ribavirin (pegIFN/RBV) in treatment-naïve and pegIFN/RBV treatment-experienced patients with chronic hepatitis C (HCV) genotype (GT) 1 or GT4 infection.

“Treatment regimens containing peginterferon and ribavirin are associated with certain serious side effects,” said Dr Jan Gerstoft, Clinic for Infectious Diseases and Rheumatology, Denmark. “This study provides evidence for the clinical potential of elbasvir/grazoprevir in chronic HCV genotype 1- or 4-infection as compared with a regimen containing peginterferon and ribavirin along with sofosbuvir.”

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page